SCHEMBL4595331

SCHEMBL4595331

O=CCN1C(=O)C=CC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 12/20 0.48
FAAH O00519 4/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
BLM P54132 2/20 0.48
GMNN O75496 1/20 0.48
THPO P40225 1/20 0.48
PMP22 Q01453 1/20 0.48
HPGD P15428 2/20 0.46
HSP90AA1 P07900 1/20 0.46
TLR9 Q9NR96 1/20 0.46
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.46
XBP1 P17861 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2496082 0.82 MGLL (0.42) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL88581 0.76 CASP3 (0.48) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL10743946 0.76 MGLL (0.46) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL23716871 0.74 MGLL (0.44) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL2463763 0.74 MGLL (0.56) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL21170285 0.72 MGLL (0.38) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL822301 0.72 MGLL (0.42) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL1955696 0.72 MGLL (0.42) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL6537077 0.72 MGLL (0.48) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL9181540 0.72 MGLL (0.48) MGLLFAAHALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12514926-B2 Splicing modulator antibody-drug conjugates and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-01-06 US disclosed
US-20250135017-A1 SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-05-01 US disclosed
CN-119405832-A Splice modulating antibody-drug conjugates and methods of use thereof 卫材R&D管理有限公司 2025-02-11 CN disclosed
CN-119405834-A Splice modulating antibody-drug conjugates and methods of use thereof 卫材R&D管理有限公司 2025-02-11 CN disclosed
CN-119405831-A Splice modulating antibody-drug conjugates and methods of use thereof 卫材R&D管理有限公司 2025-02-11 CN disclosed
CN-119405833-A Splice modulating antibody-drug conjugates and methods of use thereof 卫材R&D管理有限公司 2025-02-11 CN disclosed
US-12172986-B2 Splicing modulator antibody-drug conjugates and methods of use EISAI R&D MANAGEMENT CO., LTD (JP) 2024-12-24 US disclosed
CN-112218663-B Splice modulating antibody-drug conjugates and methods of use thereof 卫材R&D管理有限公司 2024-11-15 CN disclosed
US-20240360108-A1 SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-10-31 US disclosed
US-20240252670-A1 ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Beijing Synthetic Vaccine Biosciences Co., Ltd. (CN) 2024-08-01 US disclosed
EP-1447099-B1 Antineoplastic polyethylene conjugates of cytostatic compounds and pharmaceuticals comprising same KRATZ FELIX (DE) 2008-01-09 EP disclosed
EP-1447099-A2 Antineoplastic polyethylene conjugates of cytostatic compounds and pharmaceuticals comprising same Kratz, Felix (DE) 2004-08-18 EP disclosed
EP-0934081-B1 ANTINEOPLASTIC CONJUGATES OF ALBUMIN KRATZ FELIX (DE) 2004-06-09 EP disclosed
US-6709679-B2 CONSISTING OF NATIVE OR THIOLATED TRANSFERRIN OR ALBUMIN OR OF POLYETHYLENE GLYCOL WITH ATLEAST ONE MERCAPTAN, HYDROXY OR AMINE GROUP AND CYTOSTATIC COMPOUNDS DERIVED THROUGH MALEINIMIDE OR HYDROXYSUCCINIMIDE ESTER COMPOUNDS KRATZ FELIX (DE) 2004-03-23 US disclosed
US-20020019343-A1 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol KRATZ FELIX (DE) 2002-02-14 US disclosed
US-6310039-B1 TUMOR-INHIBITING CONJUGATES OF PROTEINS AND POLYMERS CONSISTING OF A SUITABLE CARRIER SYSTEM AND CYTOSTATIC COMPOUNDS KRATZ FELIX (DE) 2001-10-30 US disclosed
US-4785010-A AGING RESISTANCE OF HUMANS CASSELLA AKTIENGESELLSCHAFT (DE) 1988-11-15 US disclosed
EP-0124067-B1 2-(AMINOALKYL)-PYRROLE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1986-12-17 EP disclosed
EP-0124067-A1 2-(Aminoalkyl)-pyrrole derivatives, process for their manufacture and their use CASSELLA Aktiengesellschaft (DE) 1984-11-07 EP disclosed
US-4088489-A Method for the preparation of relief structures SIEMENS AKTIENGESELLSCHAFT (DT) 1978-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360108-A1 SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE RBM17, RBM22, SF3B1 MGLL 4600/4885FAAH 4427/4885ALDH1A1 2080/4885
US-20240252670-A1 ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TLR8, TLR7, PDCD1LG2 MGLL 1666/4885FAAH 3225/4885ALDH1A1 239/4885
US-20020019343-A1 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol TFRC, ALB, FOLR1 MGLL 3432/4885FAAH 1010/4885ALDH1A1 2933/4885
US-12172986-B2 Splicing modulator antibody-drug conjugates and methods of use RBM17, RBM22, SF3B1 MGLL 4600/4885FAAH 4427/4885ALDH1A1 2080/4885
US-20250135017-A1 SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE RBM17, SNRPE, HNRNPAB MGLL 4708/4885FAAH 4513/4885ALDH1A1 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.